Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study
Tobramycin Inhalation Powder
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
>= 6 Years
25 - 75 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Only participants from core study CTBM100C2401 are eligible.
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
Children's Hospital Medical Center of Akron (Pediatric), Akron, OH, 44308
Ouellette, Deborah Phone: (330) 543-3089 Email: email@example.com
Medical University of South Carolina (Adult), Charleston, SC, 29425
Warden, Ashley Phone: (843) 792-4349 Email: firstname.lastname@example.org
Baylor College of Medicine (Pediatric), Houston, TX, 77030
Schaap, Nicoline Phone: (832) 822-4252 Email: email@example.com